The Filings Report

Insmed, Inc.

INSMNasdaqCIK 1104506Healthcare / Drug Manufacturersfiscal year ends December66 quarters since 2010

Revenue, Q3 FY2026
$524M
+268.4% on Q3 FY2025
Net income
−$100M
+72.9% on Q3 FY2025
Free cash flow
−$42M
+81.1% on Q3 FY2025
Diluted EPS
$-0.46
+73.7% on Q3 FY2025
Revenue, TTM
$1.5B
trailing four quarters
Net margin, TTM
-39.9%
net income −$606M
Free cash flow, TTM
−$628M
−$596M less $32M capex
Cash and equivalents
$397M
long-term debt $545M, Sep 30, 2026
Shares, 12-month change
+2.9%
219M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$24.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Insmed, Inc. reported revenue of $524M, +268.4% on Q3 FY2025, and net loss of $100M (+72.9%). Operating margin was −17.0%. Free cash flow, operating cash flow less capital expenditures, was −$42M (−$36M less $6M). Diluted earnings per share were $-0.46.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$500M−$250M$0$250M$500M$750MQ4'22, Revenue: $59MQ4'22, Net income: −$160MQ4'22Q1'23, Revenue: $65MQ1'23, Net income: −$160MQ1'23Q2'23, Revenue: $77MQ2'23, Net income: −$245MQ2'23Q3'23, Revenue: $79MQ3'23, Net income: −$159MQ3'23Q4'23, Revenue: $84MQ4'23, Net income: −$186MQ4'23Q1'24, Revenue: $76MQ1'24, Net income: −$157MQ1'24Q2'24, Revenue: $90MQ2'24, Net income: −$301MQ2'24Q3'24, Revenue: $93MQ3'24, Net income: −$221MQ3'24Q4'24, Revenue: $104MQ4'24, Net income: −$236MQ4'24Q1'25, Revenue: $93MQ1'25, Net income: −$257MQ1'25Q2'25, Revenue: $107MQ2'25, Net income: −$322MQ2'25Q3'25, Revenue: $142MQ3'25, Net income: −$370MQ3'25Q4'25, Revenue: $264MQ4'25, Net income: −$328MQ4'25Q1'26, Revenue: $306MQ1'26, Net income: −$164MQ1'26Q2'26, Revenue: $425MQ2'26, Net income: −$13MQ2'26Q3'26, Revenue: $524MQ3'26, Net income: −$100MQ3'26−$500M−$250M$0$250M$500M$750MQ4'22, Revenue: $59MQ4'22, Net income: −$160MQ1'23, Revenue: $65MQ1'23, Net income: −$160MQ1'23Q2'23, Revenue: $77MQ2'23, Net income: −$245MQ3'23, Revenue: $79MQ3'23, Net income: −$159MQ3'23Q4'23, Revenue: $84MQ4'23, Net income: −$186MQ1'24, Revenue: $76MQ1'24, Net income: −$157MQ1'24Q2'24, Revenue: $90MQ2'24, Net income: −$301MQ3'24, Revenue: $93MQ3'24, Net income: −$221MQ3'24Q4'24, Revenue: $104MQ4'24, Net income: −$236MQ1'25, Revenue: $93MQ1'25, Net income: −$257MQ1'25Q2'25, Revenue: $107MQ2'25, Net income: −$322MQ3'25, Revenue: $142MQ3'25, Net income: −$370MQ3'25Q4'25, Revenue: $264MQ4'25, Net income: −$328MQ1'26, Revenue: $306MQ1'26, Net income: −$164MQ1'26Q2'26, Revenue: $425MQ2'26, Net income: −$13MQ3'26, Revenue: $524MQ3'26, Net income: −$100MQ3'26

Net income losses drawn in red.

Free cash flow
−$300M−$200M−$100M$0$100MQ4'22, Free cash flow: −$108MQ4'22Q1'23, Free cash flow: −$150MQ1'23Q2'23, Free cash flow: −$128MQ2'23Q3'23, Free cash flow: −$139MQ3'23Q4'23, Free cash flow: −$133MQ4'23Q1'24, Free cash flow: −$189MQ1'24Q2'24, Free cash flow: −$130MQ2'24Q3'24, Free cash flow: −$185MQ3'24Q4'24, Free cash flow: −$203MQ4'24Q1'25, Free cash flow: −$272MQ1'25Q2'25, Free cash flow: −$209MQ2'25Q3'25, Free cash flow: −$222MQ3'25Q4'25, Free cash flow: −$264MQ4'25Q1'26, Free cash flow: −$226MQ1'26Q2'26, Free cash flow: −$95MQ2'26Q3'26, Free cash flow: −$42MQ3'26−$300M−$200M−$100M$0$100MQ4'22, Free cash flow: −$108MQ1'23, Free cash flow: −$150MQ1'23Q2'23, Free cash flow: −$128MQ3'23, Free cash flow: −$139MQ3'23Q4'23, Free cash flow: −$133MQ1'24, Free cash flow: −$189MQ1'24Q2'24, Free cash flow: −$130MQ3'24, Free cash flow: −$185MQ3'24Q4'24, Free cash flow: −$203MQ1'25, Free cash flow: −$272MQ1'25Q2'25, Free cash flow: −$209MQ3'25, Free cash flow: −$222MQ3'25Q4'25, Free cash flow: −$264MQ1'26, Free cash flow: −$226MQ1'26Q2'26, Free cash flow: −$95MQ3'26, Free cash flow: −$42MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $1.1BQ4'22, Long-term debt: $1.1BQ4'22Q1'23, Cash and equivalents: $969MQ1'23, Long-term debt: $1.1BQ1'23Q2'23, Cash and equivalents: $613MQ2'23, Long-term debt: $1.1BQ2'23Q3'23, Cash and equivalents: $487MQ3'23, Long-term debt: $1.1BQ3'23Q4'23, Cash and equivalents: $482MQ4'23, Long-term debt: $1.2BQ4'23Q1'24, Cash and equivalents: $596MQ1'24, Long-term debt: $939MQ1'24Q2'24, Cash and equivalents: $1.2BQ2'24, Long-term debt: $947MQ2'24Q3'24, Cash and equivalents: $461MQ3'24, Long-term debt: $955MQ3'24Q4'24, Cash and equivalents: $555MQ4'24, Long-term debt: $1.1BQ4'24Q1'25, Cash and equivalents: $403MQ1'25, Long-term debt: $1.1BQ1'25Q2'25, Cash and equivalents: $1.3BQ2'25, Long-term debt: $539MQ2'25Q3'25, Cash and equivalents: $335MQ3'25, Long-term debt: $540MQ3'25Q4'25, Cash and equivalents: $510MQ4'25, Long-term debt: $541MQ4'25Q1'26, Cash and equivalents: $582MQ1'26, Long-term debt: $542MQ1'26Q2'26, Cash and equivalents: $545MQ2'26, Long-term debt: $544MQ2'26Q3'26, Cash and equivalents: $397MQ3'26, Long-term debt: $545MQ3'26$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $1.1BQ4'22, Long-term debt: $1.1BQ1'23, Cash and equivalents: $969MQ1'23, Long-term debt: $1.1BQ1'23Q2'23, Cash and equivalents: $613MQ2'23, Long-term debt: $1.1BQ3'23, Cash and equivalents: $487MQ3'23, Long-term debt: $1.1BQ3'23Q4'23, Cash and equivalents: $482MQ4'23, Long-term debt: $1.2BQ1'24, Cash and equivalents: $596MQ1'24, Long-term debt: $939MQ1'24Q2'24, Cash and equivalents: $1.2BQ2'24, Long-term debt: $947MQ3'24, Cash and equivalents: $461MQ3'24, Long-term debt: $955MQ3'24Q4'24, Cash and equivalents: $555MQ4'24, Long-term debt: $1.1BQ1'25, Cash and equivalents: $403MQ1'25, Long-term debt: $1.1BQ1'25Q2'25, Cash and equivalents: $1.3BQ2'25, Long-term debt: $539MQ3'25, Cash and equivalents: $335MQ3'25, Long-term debt: $540MQ3'25Q4'25, Cash and equivalents: $510MQ4'25, Long-term debt: $541MQ1'26, Cash and equivalents: $582MQ1'26, Long-term debt: $542MQ1'26Q2'26, Cash and equivalents: $545MQ2'26, Long-term debt: $544MQ3'26, Cash and equivalents: $397MQ3'26, Long-term debt: $545MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Insmed, Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue52442530626414210793104+268.4%
Cost of revenue7867474429282126+166.4%
Gross profit—————————
Research and development270210209255186177153180+44.8%
Selling, general and administrative253247247212186155148143+35.8%
Operating income(89)(2)(153)(320)(366)(313)(248)(230)+75.6%
Other income (expense)1(1)(1)(2)(1)000+275.1%
Pretax income(98)(11)(162)(327)(369)(320)(256)(234)+73.5%
Income tax32121111+102.0%
Net income(100)(13)(164)(328)(370)(322)(257)(236)+72.9%
Diluted EPS ($)(0.46)(0.06)(0.76)—(1.75)(1.70)(1.42)—+73.7%
Diluted shares (millions)219217215—212189181——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Insmed, Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents3975455825103351,284403555+18.5%
Short-term investments7506166419201,345572796879−44.2%
Total current assets1,7071,6341,6131,7941,9322,0821,4031,622−11.7%
Total assets2,2262,1032,0762,2652,3612,4801,8032,025−5.7%
Total current liabilities597439361469417312239298+43.0%
Long-term debt5455445425415405391,1051,103+1.0%
Total liabilities1,5001,3451,3711,5261,4151,2301,7041,740+6.0%
Stockholders’ equity7267577057399461,25099285−23.2%
Shares outstanding (millions)219218217216213211182181—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Insmed, Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Oct 30, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(36)(89)(223)(248)(220)(206)(262)(196)+83.4%
Capital expenditures6631723107+132.6%
Free cash flow (CFO − capex)(42)(95)(226)(264)(222)(209)(272)(203)+81.1%
Depreciation and amortization—————————
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 19, 2026.

Income statement

Insmed, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 22, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Mar 6, 2014FY2012ended Dec 31, 2012filed Mar 18, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 8, 2011FY2009ended Dec 31, 2009filed Mar 13, 2012
Revenue60636430524518816413610000—1204710
Cost of revenue123866655444024200———————
Gross profit——————11270————————
Research and development771598571398273181132145110123745644302959
Selling, general and administrative701461345266234204211168795143312213121010
Operating income(1,247)(878)(710)(457)(375)(265)(235)(307)(189)(173)(117)(87)(55)(42)(62)(8)(9)
Other income (expense)(2)02(6)(3)0(1)1000000021
Pretax income(1,272)(910)(747)(480)(436)(293)(254)(324)(193)(176)(120)(90)(57)(41)(60)(6)119
Income tax5431(2)11000(2)(10)(1)0000
Net income(1,277)(914)(750)(482)(435)(294)(254)(324)(193)(176)(118)(79)(56)(41)(60)(6)118
Diluted EPS ($)(6.42)(5.57)(5.34)(3.91)(3.88)(3.01)(3.01)———————(2.95)(0.49)9.30
Diluted shares (millions)199164140123112988577676259433527231313*

Balance sheet

Insmed, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 22, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Mar 6, 2014FY2012ended Dec 31, 2012filed Mar 18, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 8, 2011FY2009ended Dec 31, 2009filed Mar 13, 2012
Cash and equivalents5105554821,074717533487495381163283159114911511—
Short-term investments920879298740————————06197—
Total current assets1,7941,6229291,2738376235555193891682881651169477109—
Total assets2,2652,0251,3301,6561,244796742605462238357231176154140196—
Total current liabilities469298226190135119858045282220161643—
Long-term debt5411,1031,1551,1255673563363175655222516160——
Total liabilities1,5261,7401,6621,568833520481396101834545333363—
Stockholders’ equity739285(332)88410276262208361154312186143121134193124
Shares outstanding (millions)216181148136119103907877626250393225——

Cash flow statement

Insmed, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 17, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 22, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Mar 6, 2014FY2012ended Dec 31, 2012filed Mar 18, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 8, 2011FY2009ended Dec 31, 2009filed Mar 13, 2012
Operating cash flow(935)(684)(536)(400)(363)(219)(251)(258)(160)(147)(101)——(31)(30)(8)(11)
Capital expenditures33221310764213343510100
Free cash flow (CFO − capex)(968)(706)(550)(410)(371)(226)(293)(271)(163)(151)(104)——(31)(31)(8)(11)
Depreciation and amortization——659954322111001
Share repurchases—————————————————
Dividends paid—————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$39M
5 sales by 4 insiders; officers and directors $39M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$167M
169 sales by 10 insiders; officers and directors $167M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 19, 2026Koppikar UtpalDirectoraward6,139——6,139Oct 20, 2026
Oct 19, 2026Hudson PaulDirectoraward6,139——6,139Oct 20, 2026
Sep 9, 2026Brennan David RDirectoropen-market sale25,000$124.00$3M39,238Sep 11, 2026
Aug 17, 2026Sharoky Melvin MDDirectoropen-market saleindirect5,000$127.53$638K0Aug 19, 2026
Aug 10, 2026Adsett RogerChief Operating Officeroption exercise82,280$13.67$1M181,024Aug 12, 2026
Aug 10, 2026Adsett RogerChief Operating Officeroption exercise76,600$17.16$1M257,624Aug 12, 2026
Aug 10, 2026Adsett RogerChief Operating Officeroption exercise80,970$30.46$2M338,594Aug 12, 2026
Aug 10, 2026Adsett RogerChief Operating Officeropen-market sale239,850$133.27$32M98,744Aug 12, 2026
Aug 6, 2026Flammer Martina M.D.Chief Medical Officeroption exercise18,278$18.95$346K78,764Aug 7, 2026
Aug 6, 2026Flammer Martina M.D.Chief Medical Officeroption exercise8,895$25.83$230K87,659Aug 7, 2026
Aug 6, 2026Flammer Martina M.D.Chief Medical Officeropen-market sale10b5-18,895$127.00$1M78,764Aug 7, 2026
Aug 6, 2026Flammer Martina M.D.Chief Medical Officeropen-market sale10b5-118,278$129.40$2M60,486Aug 7, 2026
Jul 23, 2026Lewis WilliamChair and CEO, Directoroption exercise6,260$30.46$191K265,318Jul 24, 2026
Jul 23, 2026Lewis WilliamChair and CEO, Directoroption exercise4,440$17.16$76K269,758Jul 24, 2026
Jul 23, 2026Lewis WilliamChair and CEO, Directoropen-market sale10b5-14,828$105.62$510K264,930Jul 24, 2026
Jul 23, 2026Lewis WilliamChair and CEO, Directoropen-market sale10b5-15,872$106.43$625K259,058Jul 24, 2026
Jul 9, 2026Lewis WilliamChair and CEO, Directoroption exercise6,259$30.46$191K265,317Jul 10, 2026
Jul 9, 2026Lewis WilliamChair and CEO, Directoroption exercise4,440$17.16$76K269,757Jul 10, 2026
Jul 9, 2026Lewis WilliamChair and CEO, Directoropen-market sale10b5-15,005$116.55$583K264,752Jul 10, 2026
Jul 9, 2026Lewis WilliamChair and CEO, Directoropen-market sale10b5-12,335$117.62$275K262,417Jul 10, 2026
Jul 9, 2026Lewis WilliamChair and CEO, Directoropen-market sale10b5-13,359$118.52$398K259,058Jul 10, 2026
Jul 6, 2026Flammer Martina M.D.Chief Medical Officeroption exercise7,945$29.13$231K68,431Jul 8, 2026
Jul 6, 2026Flammer Martina M.D.Chief Medical Officeroption exercise4,357$19.74$86K72,788Jul 8, 2026
Jul 6, 2026Flammer Martina M.D.Chief Medical Officeropen-market sale10b5-14,854$109.02$529K67,934Jul 8, 2026
Jul 6, 2026Flammer Martina M.D.Chief Medical Officeropen-market sale10b5-17,448$110.60$824K60,486Jul 8, 2026

Full insider history for Insmed, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held INSM in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded INSM by quarter.

FundManagerQuarterValueSharesWeightMove
Duquesne Family OfficeStanley DruckenmillerQ2 2026$152M1M2.92%added +23.4%
Baron Capital GroupRon BaronQ2 2026$1M10,0000.00%trimmed −50.0%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
INSMED INC, CIK 1104506 on EDGAR
Extract generated
November 1, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: other income FY2013
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2011, other income FY2012
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): InvestmentIncomeNonoperating, NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: not filed
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/INSM.json